Abstract
The SARS coronavirus 2 (SARS CoV-2) causes Coronavirus Disease (COVID-19), is an emerging viral infection. SARS CoV-2 infects target cells by attaching to Angiotensin-Converting Enzyme (ACE2). SARS CoV-2 could cause cardiac damage in patients with severe COVID-19, as ACE2 is expressed in cardiac cells, including cardiomyocytes, pericytes, and fibroblasts, and coronavirus could directly infect these cells. Cardiovascular disorders are the most frequent comorbidity found in COVID-19 patients. Immune cells such as monocytes, macrophages, and T cells may produce inflammatory cytokines and chemokines that contribute to COVID-19 pathogenesis if their functions are uncontrolled. This causes a cytokine storm in COVID-19 patients, which has been associated with cardiac damage. Tregs are a subset of immune cells that regulate immune and inflammatory responses. Tregs suppress inflammation and improve cardiovascular function through a variety of mechanisms. This is an exciting research area to explore the cellular, molecular, and immunological mechanisms related to reducing risks of cardiovascular complications in severe COVID-19. This review evaluated whether Tregs can affect COVID-19-related cardiovascular complications, as well as the mechanisms through which Tregs act.
【저자키워드】 COVID-19, SARS CoV-2, Treatment, cardiovascular complications, Tregs, 【초록키워드】 Monocytes, Inflammation, viral infection, ACE2, Cytokine storm, coronavirus, macrophages, severe COVID-19, Inflammatory responses, Comorbidity, risk, chemokine, immune, cardiovascular, T cell, Cardiovascular function, COVID-19 pathogenesis, cells, Research, Patient, mechanisms, pericytes, molecular, SARS Coronavirus, cardiac damage, mechanism, function, Inflammatory cytokine, Treg, COVID-19 patients, cellular, fibroblasts, Immune cell, regulate, immunological mechanism, target cell, cardiovascular complication, These cells, disorder, infect, Affect, Cell, IMPROVE, evaluated, contribute, variety, reducing, expressed, cause, suppress, subset, 【제목키워드】 severe COVID-19, Regulatory T cell, Patient, cardiovascular complication, therapeutic potential, reducing,